Navarro-Ledesma Santiago, Carroll James D, González-Muñoz Ana, Burton Patricia
Department of Physiotherapy, Faculty of Health Sciences, University of Granada, Melilla, Spain.
THOR Photomedicine Ltd., London, United Kingdom.
Front Neurosci. 2024 Jan 31;18:1264821. doi: 10.3389/fnins.2024.1264821. eCollection 2024.
The management of fibromyalgia (FM) symptoms on a global scale remains a complex endeavor. This study endeavors to assess the impact of whole-body photobiomodulation (PBM) compared to placebo PBM on pain, functionality, and psychological symptoms in individuals afflicted with fibromyalgia.
The primary objectives of this research were to conduct a comparative analysis of the effects of whole-body photobiomodulation (PBM) and placebo PBM on pain, functionality, and psychological symptoms in patients suffering from fibromyalgia (FM).
A total of 42 subjects were recruited from a private care practice for participation in this triple-blinded, placebo-controlled, randomized clinical trial. Participants underwent 12 treatment sessions, and assessments were conducted at various intervals, including baseline (T0), midway through the 12-session treatment (T1), at the completion of the 12 sessions (T2), and follow-ups at 2 weeks (T3), 3 months (T4), and 6 months (T5).
Statistical analysis revealed significant reductions in pain at T2, T3, and T5. Additionally, quality of life exhibited marked improvements after sessions at T1, T2, T3, T4, and T5. Leisure activity also demonstrated statistically significant improvements at T2, T3, T4, and T5. Furthermore, kinesiophobia showed significant differences between groups immediately after treatment at T2, T3, T4, and T5. Self-efficacy, when compared between groups, demonstrated significant differences at T3, T4, and T5 (two weeks after treatment). Lastly, pain catastrophizing exhibited significant differences only at T5.
The findings of this study indicate that whole-body PBM treatment for 4 weeks resulted in significant pain reduction and improved quality of life in individuals suffering from FM. Furthermore, kinesiophobia and self-efficacy demonstrated improvements in both short-term and long-term assessments, while pain catastrophizing showed improvement at the 6-month follow-up. Consequently, whole-body PBM emerges as a promising multifactorial treatment option for FM patients, though further studies are required to validate and strengthen these results.Clinicaltrials.gov, NCT0424897.
在全球范围内，纤维肌痛（FM）症状的管理仍是一项复杂的工作。本研究旨在评估全身光生物调节（PBM）与安慰剂PBM相比，对纤维肌痛患者疼痛、功能和心理症状的影响。
本研究的主要目的是对全身光生物调节（PBM）和安慰剂PBM对纤维肌痛（FM）患者疼痛、功能和心理症状的影响进行比较分析。
从一家私人护理机构招募了42名受试者，参与这项三盲、安慰剂对照、随机临床试验。参与者接受了12次治疗，在不同时间点进行评估，包括基线（T0）、12次治疗中途（T1）、12次治疗结束时（T2）以及2周（T3）、3个月（T4）和6个月（T5）的随访。
统计分析显示，在T2、T3和T5时疼痛显著减轻。此外，在T1、T2、T3、T4和T5治疗后，生活质量有显著改善。休闲活动在T2、T3、T4和T5时也有统计学上的显著改善。此外，在T2、T3、T4和T5治疗后，恐动症在两组之间立即显示出显著差异。两组之间比较，自我效能感在T3、T4和T5（治疗后两周）时有显著差异。最后，疼痛灾难化仅在T5时有显著差异。
本研究结果表明，为期4周的全身PBM治疗可显著减轻FM患者的疼痛并改善生活质量。此外，恐动症和自我效能感在短期和长期评估中均有改善，而疼痛灾难化在6个月随访时有改善。因此，全身PBM成为FM患者一种有前景的多因素治疗选择，不过需要进一步研究来验证和强化这些结果。Clinicaltrials.gov，NCT0424897。
